Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials

cancer, clinical trials, research funding, Canada, high-income countries

This document reviews Canadian involvement in oncology randomized controlled trials (RCTs) from 2014-2017, comparing them to those from other high-income countries (HICs). Canada contributed to 155 (24%) of 636 HIC-led RCTs. Canadian RCTs focused more on palliative care (72%) compared to 62% in …

Apr 13^th • 10 mins read

Safeguarding cancer research funding by European charities amidst the COVID-19 pandemic

cancer charities, cancer research, COVID‐19, funding, pandemic, policy, AECC, AIRC

The COVID-19 outbreak has had a significant impact on cancer research and cancer care. European cancer charities are required to reassess their strategies. There is a need to safeguard income and provide support to cancer researchers. It is crucial to sustain cancer research funding during thes…

Nov 22^nd • 3 mins read

Patient burden and clinical advances associated with post approval monotherapy cancer drug trials: a retrospective cohort study

clinical advances, monotherapy cancer drug trials, FDA

Objective: The study investigates the efforts to extend the uses of new drugs by testing them for new, non-approved indications and examines the patient burden and clinical impact. Design and Setting: A retrospective cohort study focused on post-approval trials of anticancer drugs approved betwee…

Feb 17^th • 7 mins read